<DOC>
	<DOCNO>NCT01037699</DOCNO>
	<brief_summary>To analyse impact cycle outcome LH supplementation ovarian stimulation control GnRH antagonist two age group : patient upto 35 year old , patient age 36 39 year old .</brief_summary>
	<brief_title>Luteinizing Hormone ( LH ) Supplementation Gonadotropin-releasing Hormone ( GnRH ) Antagonist Cycles</brief_title>
	<detailed_description>All patient receive oral contraceptive pill 0.030 mg ethinyl-estradiol 3.0 mg drospirenone cycle prior ovarian stimulation . On second day menstruation , patient start ovarian stimulation follow : Patients &lt; 36 : 225 IU/day recombinant FSH ( FSH alone group ) 150 IU rFSH 75 IU rLH/day ( FSH+LH group ) 5 day . On day 6 , 0.25 mg/day dose GnRH antagonist Cetrorelix add day rCG administration . Patients 36-39 : Initial dose 300 IU rFSH /day ( FSH alone group ) ) 225 IU rFSH 75 IU rLH/day ( FSH + LH group ) 5 day . On day 6 , 0.25 mg/day dose GnRH antagonist Cetrorelix add day rCG administration . A maximum 3 embryo transfer day 3 embryo development .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>1st2nd IVF cycle . Age 39 year old BMI : 1829.9 . Basal FSH &lt; 12 IU/L LH : FSH &gt; 2 ( PCO ) Low response background ( &lt; 5 oocyte ) Endometrioma Recurrent pregnancy loss Any preimplantational genetic diagnosis indication Any systemic , metabolic endocrinological disorder .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Ovarian stimulation</keyword>
	<keyword>In Vitro Fertilization</keyword>
	<keyword>Luteinizing Hormone</keyword>
	<keyword>GnRH antagonist</keyword>
	<keyword>Implantation rate infertile patient undergo In vitro fertilization embryo transfer .</keyword>
</DOC>